Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.66 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.66 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.58 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.58 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928412 | 0.96 | CHRNB4 (0.72) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL1928695 | 0.96 | CHRNB4 (0.72) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL29772002 | 0.87 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL11448897 | 0.86 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL14578209 | 0.85 | CHRNB4 (0.74) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL10881783 | 0.84 | CHRNB4 (0.68) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL11448129 | 0.83 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL10874140 | 0.80 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL6673010 | 0.80 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL14559958 | 0.79 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | CHRNB4 2214/4885CHRNA3 1243/4885CHRNB2 2067/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | CHRNB4 2471/4885CHRNA3 1614/4885CHRNB2 2195/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | CHRNB4 2214/4885CHRNA3 1243/4885CHRNB2 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.